Articles

Continuing the Learning Process

Creating truly patient-centered cancer care would be the main goal of Elizabeth Beisel, Swim Across America Representative.

By Elizabeth Beisel

Amazing Array of Experts at AVBCC Summit

As a newcomer to the oncology world, Elizabeth Beisel, Swim Across America Representative, looks forward to attending the next AVBCC Summit to build on all she has learned from her first meeting.

By Jack Salerno

It's Personal and Professional for This Attendee

Jack Salerno, Managing Partner, SBD Partners, says he has attended the AVBCC Summit for the past 4 years because "it is a really great event with an amazing array of experts in oncology healthcare."

By Jack Salerno

Listening to Learn at AVBCC Summit

Key takeaways for Jack Salerno, Managing Partner, SBD Partners, are personal and professional. He mentions the energy, passion, and commitment on display at each summit.

By Jack Salerno

Patients with Advanced Myelofibrosis Receiving Bomedemstat Exhibit Improved Clinical Outcomes Compared to JAK Inhibitors

"You don't learn anything when you're talking; you learn when you listen," and Jack Salerno, Managing Partner, SBD Partners, comes to learn and share information for better patient outcomes.

TGFβ-Regulated Progression of Thrombocytopenia Reduced in Patients with Advanced Myelofibrosis Receiving AVID200 Therapy

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib.

Tagraxofusp Monotherapy Demonstrated Clinical Efficacy in Patients with Advanced Myelofibrosis and Refractory to JAK Inhibitor Therapy

TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia.

Association Between IPSS Score and JAK Mutation Characterize Patients with Myelofibrosis at High Risk for Thrombosis

JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data.